Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02208362
Recruitment Status : Recruiting
First Posted : August 5, 2014
Last Update Posted : January 13, 2020
National Cancer Institute (NCI)
Gateway for Cancer Research
Mustang Bio, Inc.
California Institute for Regenerative Medicine (CIRM)
Information provided by (Responsible Party):
City of Hope Medical Center